logo
Chinese Man Hospitalised With Collapsed Lungs After Acupuncture Session

Chinese Man Hospitalised With Collapsed Lungs After Acupuncture Session

NDTV14-05-2025

In a concerning incident from Henan province, China, a man identified as Mr Gao narrowly escaped death after undergoing acupuncture treatment from an unlicensed practitioner to address a benign tumour, according to the South China Morning Post. Diagnosed with a fibroma beneath his shoulder blade, Mr Gao sought alternative treatment through a referral from his wife, Mrs Zhang. The practitioner, lacking formal medical qualifications, misdiagnosed the tumour as an "air bump" and claimed it could be treated with acupuncture.
The initial session took place on February 22 in the lounge of a cybercafe owned by a friend. Shortly after needles were inserted into his back, Mr Gao experienced severe breathing difficulties and lost control of his bodily functions. He was rushed to a hospital, where doctors diagnosed him with respiratory failure and pneumothorax-conditions indicating his lungs had been punctured. Medical professionals stated that any further delay could have been fatal.
According to SCMP, Initially, the unqualified doctor said he would take responsibility but later disappeared and blocked Zhang online. Zhang sought help from Henan TV and went to the man's home. There, the man's father revealed that his son was a so-called barefoot doctor, meaning he did not have a medical licence.
He said his son learnt massage and acupuncture from watching other people do it.
Zhang's friend said he introduced the man to the couple because he had received multiple treatments from him, and he had successfully "cured" his problems, such as neck pains.
As per Chinese law, a person who performs medical procedures without a licence and causes serious harm to a patient's health can face three to 10 years in jail. Social media was shocked by the ignorance of the couple and their friend.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lupin inks pact with China's Sino Universal for Tiotropium inhaler supply
Lupin inks pact with China's Sino Universal for Tiotropium inhaler supply

Business Standard

time3 hours ago

  • Business Standard

Lupin inks pact with China's Sino Universal for Tiotropium inhaler supply

Pharma major Lupin Ltd on Monday said it has signed a license and supply agreement with China's Sino Universal Pharmaceuticals for the commercialisation of Tiotropium dry powder inhaler in the Chinese market. The agreement pertains to the commercialisation of the Tiotropium dry powder inhaler of strength 18 mcg/capsule, which is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD), Lupin said in a regulatory filing. Under the agreement, Sino Universal Pharmaceuticals (SUP) will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorisation holder and responsible for manufacturing of the product, it added. "This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector," Lupin President Corporate Development, Fabrice Egros said. With SUP, the company aim to enhance patient access to innovative and high-quality healthcare solutions, Egros added. Commenting on the partnership, SUP President Wang Li said, "Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care." By bringing more efficient and superior products to market, Li said, "We aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin said the partnership will enable it to expand its footprint in China. Tiotropium dry powder inhaler is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions, Lupin said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler
Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler

Time of India

time3 hours ago

  • Time of India

Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler

Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Pharma major Lupin Ltd on Monday said it has signed a license and supply agreement with China's Sino Universal Pharmaceuticals for the commercialisation of Tiotropium dry powder inhaler in the Chinese agreement pertains to the commercialisation of the Tiotropium dry powder inhaler of strength 18 mcg/capsule, which is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD), Lupin said in a regulatory the agreement, Sino Universal Pharmaceuticals (SUP) will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorisation holder and responsible for manufacturing of the product, it added."This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector," Lupin President Corporate Development, Fabrice Egros SUP, the company aim to enhance patient access to innovative and high-quality healthcare solutions , Egros on the partnership, SUP President Wang Li said, "Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care."By bringing more efficient and superior products to market, Li said, "We aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health."Lupin said the partnership will enable it to expand its footprint in dry powder inhaler is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions, Lupin said. PTI

China joins US in brain implant race with successful clinical trial test
China joins US in brain implant race with successful clinical trial test

Business Standard

time3 hours ago

  • Business Standard

China joins US in brain implant race with successful clinical trial test

Chinese researchers used brain-computer interfaces, or BCI, a wireless invasive implant in a patient with tetraplegia in March Bloomberg China's first clinical trial of a technology that allows signals from the brain to control an external device has proved successful, making it only the second country after the US to reach this stage, according to the Global Times. Chinese researchers used brain-computer interfaces, or BCI, a wireless invasive implant in a patient with tetraplegia in March, the English-language newspaper reported. Only a few weeks after the surgery, the patient was able to play racing games and chess on the computer using only the mind to control the electronic devices, it said, citing a statement from the Shanghai-based Center for Excellence in Brain Science and Intelligence Technology. BCI is an emerging technology to help restore functionality to people with paralysis, and Neuralink Corp., co-founded by Elon Musk, is at the forefront of this research. The implant used in the Chinese trial is the world's smallest so far, with a diameter of 26 millimeters and thickness less than 6 millimeters, the Global Times said, adding that it's over 100 times more flexible than the one developed by Neuralink. For the next stage, the team plans to enable the patient to operate a robotic arm using thoughts to perform more complex physical actions as such grasping and holding a cup. The center launched the trial in collaboration with Fudan University's Huashan Hospital. Beijing has reported some experiments with implants by startup companies over the past months, but the clinical trial shows China is in a tight race with the US in developing this frontier technology. The center said the BCI system could get approval from the authorities, and be able to enter the market as early as 2028.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store